(±)-8-aminooctanoic acid 2,5,7,8-tetramethyl-2-[4-(3-methyl-2,4-dioxothiazolidin-(5Z)-ylidenemethyl)phenoxymethyl]chroman-6-yl ester trifluoroacetic acid salt | 1448960-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: (±)-8-aminooctanoic acid 2,5,7,8-tetramethyl-2-[4-(3-methyl-2,4-dioxothiazolidin-(5Z)-ylidenemethyl)phenoxymethyl]chroman-6-yl ester trifluoroacetic acid salt
• 英文别名: {2,5,7,8-tetramethyl-2-[4-(5Z)-(3-methyl-2,4-dioxothiazolidin-5-ylidenemethyl)phenoxymethyl]chroman-6-yl} 8-aminooctanoate trifluoroacetate；[2,5,7,8-tetramethyl-2-[[4-[(Z)-(3-methyl-2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy]methyl]-3,4-dihydrochromen-6-yl] 8-aminooctanoate;2,2,2-trifluoroacetic acid
• CAS: 1448960-21-1
• 化学式: C₂HF₃O₂*C₃₃H₄₂N₂O₆S
• 分子量: 708.796
• InChiKey: YEKBSAVGVADXLB-MORRFHCESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.28
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  171
• 氢给体数：
  2
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  8-tert-butoxycarbonylamino-octanoic acid 2-{4-[2,4-dioxo-thiazolidin-(5Z)-ylidenemethyl]-phenoxymethyl}-2,5,7,8-tetramethyl-chroman-6-yl ester 在 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 (±)-8-aminooctanoic acid 2,5,7,8-tetramethyl-2-[4-(3-methyl-2,4-dioxothiazolidin-(5Z)-ylidenemethyl)phenoxymethyl]chroman-6-yl ester trifluoroacetic acid salt
  参考文献：
  名称：

  THIAZOLIDINEDIONE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN CANCER TREATMENT

  摘要：

  本发明涉及噻唑烷二酮衍生物、其制备方法以及预防或治疗癌症（更具体地说是乳腺癌）的治疗用途。这些化合物的化学式为（I），在浓度为100μM时，具有肝细胞存活率优选大于60％，更优选大于80％，最优选大于85％。

  公开号：

  US20140364465A1

文献信息

• Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds
  作者：Andrea Bordessa、Christelle Colin-Cassin、Isabelle Grillier-Vuissoz、Sandra Kuntz、Sabine Mazerbourg、Gauthier Husson、Myriam Vo、Stéphane Flament、Hélène Martin、Yves Chapleur、Michel Boisbrun

  DOI：10.1016/j.ejmech.2014.06.015

  日期：2014.8

  Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 μM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 μM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.